Taysha Gene Therapies Inc (TSHA)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 03-2026 | 12-2025 | 09-2025 | 06-2025 | 03-2025 | |
| Sales | 0 | 5,485 | 0 | 1,986 | 2,302 |
| Gross Profit | N/A | 5,485 | N/A | 1,986 | 2,302 |
| Operating Expenses | 43,486 | 33,785 | 34,024 | 28,739 | 23,723 |
| Operating Income | -43,486 | -28,300 | -34,024 | -26,753 | -21,421 |
| Interest Expense | 9 | 12 | 15 | 17 | 19 |
| Other Income | 1,085 | 461 | 1,306 | -112 | -89 |
| Pre-tax Income | -42,410 | -27,851 | -32,733 | -26,882 | -21,529 |
| Net Income Continuous | -42,410 | -27,851 | -32,733 | -26,882 | -21,529 |
| Net Income | $-42,410 | $-27,851 | $-32,733 | $-26,882 | $-21,529 |
| EPS Basic Total Ops | -0.12 | -0.08 | -0.09 | -0.09 | -0.08 |
| EPS Basic Continuous Ops | -0.12 | -0.08 | -0.09 | -0.09 | -0.08 |
| EPS Diluted Total Ops | -0.12 | -0.08 | -0.09 | -0.09 | -0.08 |
| EPS Diluted Continuous Ops | -0.12 | -0.08 | -0.09 | -0.09 | -0.08 |
| EPS Diluted Before Non-Recurring Items | -0.12 | -0.08 | -0.09 | -0.09 | -0.08 |
| EBITDA(a) | $-43,191 | $-28,001 | $-33,738 | $-26,476 | $-21,138 |